Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...

Vertex Pharma has secured FDA approval for its ... broad label to treat adults with moderate-to-severe acute pain - for example, after trauma or surgery - and works by blocking a pain-signalling ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Vertex valuation multiples have reached unsustainable heights at ~11x forward revenue, which increases its risk for a correction. Vertex specializes in corporate tax compliance software, targeting ...

Google is following the 2.0 Flash launch with new test models in the Gemini app: 2.0 Pro Experimental and 2.0 Flash Thinking ...

Bank of America analysts said in a research note that the deal “adds strategic value and further bolsters Vertex’s long-term growth profile,” and is an example of the company “putting its ...